Pediatric-onset multiple sclerosis represents around 3-53-5% all patients with multiple sclerosis.
Neuroprotective therapies, specifically focusing on the prevention of oxidative damage may, thus, become attractive in the future, and a current trial testing the effect of fumarates, which boost endogenous antioxidant enzymes in patients with multiple sclerosis, represents one possible example for this approach (Schreibelt et al., 2007; de Vries et al., 2008; Linker et al., 2011).
Parkinson's disease and multiple sclerosis represent a lower proportion of persons with this specific admission.
Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults, exhibiting considerable clinical, radiological and pathological heterogeneity.
In general, at the disease onset an estimated 85 90% of patients have a relapsing-remitting clinical course that is characterized by clearly defined relapses with full or partial recovery, whereas the remaining 10 15% have primary-progressive multiple sclerosis, which represents a relentless progression from the beginning with no remission (Compston and Coles, 2008).
The most likely explanation comes from our observation that oxidized DNA and lipids were mainly present in a small zone of active multiple sclerosis lesions, which represents that previously described as the area of initial demyelination (Marik et al., 2007) or the 'prephagocytic' lesion (Barnett and Prineas, 2004; Henderson et al., 2009).
The most common clinical form is relapsing-remitting multiple sclerosis (RRMS) which can represent up to 65% of all patients with MS [2].
As it can be seen, multiple sclerosis is by far the most represented class, with 22.2% of the references, followed by the rheumatoid arthritis, diabetes and lupus categories all represented by similar numbers of references in the 10 to 17% range.
Experimental Autoimmune Encephalomyelitis (EAE), an animal model representing human multiple sclerosis (MS), is mediated by CD4+ helper T cells which trigger an (auto -inflammatory response auto -inflammatoryresponsestem (CNS) structures thagainstinates in demyelination, axonal damage and paralysis.
Fine mapping of actively demyelinating lesions in multiple sclerosis revealed several different zones, representing the evolution of the plaques (Figs 1A F, 2A G).
For years we have been representing people with multiple sclerosis, Parkinson's disease and other debilitating conditions who have been unfairly denied care needed to reduce pain and spasticity or to slow their decline.
